The American Journal of Managed Care

Study: Long-chain Noncoding RNA Expression Correlates with SLE, Inflammation

Of 5 RNA investigated, 2 correlated with systemic lupus erythematosus and the last correlated with certain inflammation-related symptoms. Expression levels of some long-chain noncoding RNA appear to ...
The American Journal of Managed Care

Study: Patients With SLE, AF Experience Higher In-Hospital Mortality Rate

Patients with systemic lupus erythematosus (SLE) and atrial fibrillation (AF) exhibited elevated risks of severe cardiac complications, alongside increased in-hospital mortality, costs, and length of ...
Lupus Science & Medicine

High incidence of herpes zoster among SLE patients in Indonesia: a retrospective cohort study

Objective Systemic lupus erythematosus (SLE) is associated with increased susceptibility to infections, including herpes ...
Business Insider

Study Published in The Lancet Shows Benefit of Baricitinib 4 mg for the Treatment of Systemic Lupus Erythematosus (SLE)

INDIANAPOLIS, July 19, 2018 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) and Incyte Corporation (NASDAQ: INCY) announced today that results of a global systemic lupus erythematosus (SLE) Phase 2 ...
RMD Open

Distinct pattern of comorbidities hinders treatment target attainment in SLE through persistent disease activity and delayed glucocorticoid tapering: longitudinal data fro…

Background Remission and low-disease activity are recommended targets in systemic lupus erythematosus (SLE), yet many ...
Renal & Urology News

Epidemiologic Study Compares SLE Manifestations in Different Racial Groups

SLE Investigators examined racial/ethnic differences in manifestations of lupus and in the timing and risk of developing severe manifestations. Racial and ethnic makeup can influence a patient’s risk ...
Morningstar

Johnson & Johnson unveils new data showing nipocalimab is the first and only investigational FcRn blocker with potential to reduce systemic lupus erythematosus (SLE) activity ...

SPRING HOUSE, Pa., Jan. 6, 2026 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) today announced positive topline results from the Phase 2b JASMINE (NCT04882878) study of adults living with systemic ...